Nextcea — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Nextcea is a privately held, revenue-generating biotech services company founded in 2006 (contradicting some data showing 2018) and headquartered in Woburn, Massachusetts. It operates a specialized contract research model, providing biomarker quantification and analytical services to support drug development, primarily in neurodegenerative diseases and oncology. The company possesses proprietary biomarker panels and a technology platform centered on UPLC-MS/MS, and it engages in active intellectual property litigation to protect its assets. Its strategy is built on deep scientific expertise in specific biological pathways and collaborations with major research foundations.

OncologyImmunologyNeurodegenerative Diseases

Technology Platform

Proprietary biomarker quantification services using advanced UPLC-MS/MS 7500 platforms integrated with a LIMS system. Specializes in assays for phosphorylated LRRK2, GBA activity, BTK occupancy, and phospholipidosis/kidney safety biomarkers.

Opportunities

Growing demand for precision biomarker data in neurodegenerative disease and oncology drug development creates a expanding market for its specialized services.

The rise of new drug modalities like oligonucleotides increases need for its specialized safety assessment panels.

Successful defense of its patents could strengthen its market position and create licensing revenue.

Risk Factors

Revenue is dependent on pharmaceutical R&D spending and the clinical progress of drugs targeting its specific biomarker pathways (LRRK2, BTK).

Ongoing patent litigation is costly and carries the risk of an unfavorable outcome that could undermine its competitive edge.

Faces competition from both niche specialists and large, full-service CROs with greater resources.

Competitive Landscape

Nextcea competes in the bioanalytical CRO and specialized biomarker services market. It faces competition from large global CROs (e.g., LabCorp, IQVIA) that offer broad mass spectrometry services, as well as from smaller niche players focusing on specific diseases or technologies. Its differentiation is its deep, proprietary expertise in a select set of high-value biomarkers for neurology and oncology.

More companies in Diagnostics & Precision Medicine →More companies in United States →